Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Study reveals why GBM is highly resistant to current chemotherapies

Study reveals why GBM is highly resistant to current chemotherapies

Engineered proteins demonstrate flu-fighting potency

Engineered proteins demonstrate flu-fighting potency

Personalized medicine and the Human Genome Project

Personalized medicine and the Human Genome Project

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

AAPS honors Morphotek with 2012 Excellence in Ligand Binding Assays Award

AAPS honors Morphotek with 2012 Excellence in Ligand Binding Assays Award

Acorda Therapeutics launches Ampyra Dialogues on World MS Day

Acorda Therapeutics launches Ampyra Dialogues on World MS Day

USPTO issues patent to Corgenix’s AspirinWorks technology

USPTO issues patent to Corgenix’s AspirinWorks technology

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

AVEO commences AV-203 Phase 1 study in advanced solid tumors

AVEO commences AV-203 Phase 1 study in advanced solid tumors

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Biomarker neutralizes effect of bevacizumab in pancreas and kidney cancer patients

Biomarker neutralizes effect of bevacizumab in pancreas and kidney cancer patients

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Biologists engineer algae to produce potential candidates for malarial vaccine

Biologists engineer algae to produce potential candidates for malarial vaccine

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.